Welcome to our dedicated page for X4 Pharmaceuticals SEC filings (Ticker: XFOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
X4 Pharmaceuticals director Bridger Gary received a new stock option grant. On 01/01/2026, he was awarded options to purchase 110,000 shares of X4 Pharmaceuticals common stock at an exercise price of $4.00 per share, expiring on 01/01/2036.
The options will vest in full only if stockholders approve an increase in the share reserve under the company’s Amended and Restated 2017 Equity Incentive Plan at the company’s 2026 annual meeting of stockholders, and if he continues providing services through that date. This filing reports an equity-based compensation grant rather than a share sale.
X4 Pharmaceuticals (XFOR) filed its Q3 2025 10‑Q, highlighting early commercial traction, a major partnership, and cost actions. Total revenue was $1.8 million for the quarter, driven by $1.6 million in U.S. product sales of XOLREMDI and $0.2 million of license and other revenue. For the nine months, revenue reached $32.5 million, primarily from $28.3 million recognized under the Norgine license and supply agreement.
The company reported a Q3 net loss of $29.8 million and a nine‑month net loss of $55.3 million. Cash, cash equivalents and short‑term marketable securities were $122.2 million as of September 30, 2025. Long‑term debt stood at $76.1 million. A 1‑for‑30 reverse stock split was effected on April 28, 2025.
X4 executed significant financings: approximately $81.0 million in net proceeds from an August private placement and approximately $145.6 million in net proceeds from an October underwritten offering. The company undertook two restructurings in 2025, including an additional ~50% workforce reduction announced in September, recording about $4.9 million of related Q3 charges and ending Q3 with $3.7 million of accrued severance. As of October 31, 2025, shares outstanding were 87,436,688.
X4 Pharmaceuticals (XFOR) filed its Q3 2025 10‑Q, highlighting early commercial traction, a major partnership, and cost actions. Total revenue was $1.8 million for the quarter, driven by $1.6 million in U.S. product sales of XOLREMDI and $0.2 million of license and other revenue. For the nine months, revenue reached $32.5 million, primarily from $28.3 million recognized under the Norgine license and supply agreement.
The company reported a Q3 net loss of $29.8 million and a nine‑month net loss of $55.3 million. Cash, cash equivalents and short‑term marketable securities were $122.2 million as of September 30, 2025. Long‑term debt stood at $76.1 million. A 1‑for‑30 reverse stock split was effected on April 28, 2025.
X4 executed significant financings: approximately $81.0 million in net proceeds from an August private placement and approximately $145.6 million in net proceeds from an October underwritten offering. The company undertook two restructurings in 2025, including an additional ~50% workforce reduction announced in September, recording about $4.9 million of related Q3 charges and ending Q3 with $3.7 million of accrued severance. As of October 31, 2025, shares outstanding were 87,436,688.
X4 Pharmaceuticals, Inc. filed an 8-K stating it furnished a press release announcing financial results and other business highlights for the third quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and incorporated by reference. The company notes the Item 2.02 information is furnished, not filed, under the Exchange Act.
X4 Pharmaceuticals, Inc. filed an 8-K stating it furnished a press release announcing financial results and other business highlights for the third quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and incorporated by reference. The company notes the Item 2.02 information is furnished, not filed, under the Exchange Act.
X4 Pharmaceuticals (XFOR) Executive Chairman, also a director, reported a grant of stock options for 2,329,154 shares at an exercise price of $1.42 per share. The options were granted on August 12, 2025 and became eligible to vest after a performance-based condition was satisfied on October 29, 2025.
One third of the shares underlying the option vest on August 12, 2026, with the remainder vesting in equal monthly installments over the following 24 months, subject to continued service. The options expire on August 12, 2035.
X4 Pharmaceuticals (XFOR) reported an insider equity award. The company’s President filed a Form 4 disclosing stock options to purchase 2,329,154 shares at an exercise price of $1.42. The options were granted on August 12, 2025 and became subject to reporting when a performance-based vesting condition was satisfied on October 29, 2025.
One third of the shares subject to the option will vest on August 12, 2026, with the remaining shares vesting in equal monthly installments over the following 24 months, contingent on continued service. The options expire on August 12, 2035. Following the reported transaction, 2,329,154 derivative securities were beneficially owned, held directly.
X4 Pharmaceuticals (XFOR) filed a Form 4 reporting a stock option grant to its Chief Financial Officer, David Kirske. The filing lists 1,552,769 stock options with an exercise price of $1.42 and an expiration date of 08/12/2035.
According to the disclosure, the options were granted on 08/12/2025 and were subject to a performance-based vesting condition that was satisfied on 10/29/2025. One third of the shares subject to the option will vest on 08/12/2026, with the remainder vesting in equal monthly installments over the following 24 months, contingent on continued service. Following the reported transaction, 1,552,769 derivative securities are shown as beneficially owned, held directly.
X4 Pharmaceuticals (XFOR) reported an insider purchase by its Executive Chairman and Director. On 10/23/2025, the insider bought 86,206 shares of common stock at $2.90 per share, as disclosed on Form 4.
The filing notes the shares were purchased in connection with the company’s public offering. Following the transaction, the insider beneficially owned 376,087 shares, held directly.
X4 Pharmaceuticals announced an underwritten public offering of 45,860,000 shares of common stock at $2.90 per share and, in lieu of shares to certain investors, pre-funded warrants for 700,000 shares at $2.899 per warrant. The underwriters’ 30‑day option to purchase up to 6,984,000 additional shares was exercised in full on October 24, 2025.
The company expects net proceeds of approximately $145.6 million, after underwriting discounts, commissions, and estimated expenses. The securities were offered off an effective shelf registration, with a final prospectus supplement filed October 24, 2025. Closing is expected on October 27, 2025, subject to standard conditions. The pre-funded warrants are exercisable at any time, subject to beneficial ownership limits of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ prior notice.
X4 Pharmaceuticals launched a public offering of 45,860,000 shares of common stock and, in lieu of shares for certain investors, pre-funded warrants to purchase 700,000 shares. The public offering price is $2.90 per share and $2.899 per pre-funded warrant, for gross proceeds of $135,023,300. After underwriting discounts and estimated expenses, expected net proceeds are about $126.6 million. Underwriters have a 30‑day option to buy up to 6,984,000 additional shares.
X4 intends to use proceeds to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders and for general corporate purposes. Pre‑funded warrants carry a $0.001 exercise price, are immediately exercisable, do not expire, and are subject to ownership limits; they will not be listed. Common stock trades on Nasdaq as XFOR. Shares outstanding would be 53,819,947 after the offering, assuming no warrant exercises and no option exercise. The company estimates immediate dilution of $1.02 per share to new investors.
X4 Pharmaceuticals filed a preliminary prospectus supplement for a primary offering of common stock and, for certain investors, pre-funded warrants. The pre-funded warrants are priced at the share offering price minus $0.001 (their exercise price), are exercisable immediately, do not expire, and include an ownership cap of 9.99% (or 4.99% at the holder’s election). The underwriters have a 30-day option to purchase additional shares at the public offering price, less the underwriting discount.
X4 expects to use net proceeds, together with existing cash and cash flows from operations, to fund the pivotal Phase 3 development of mavorixafor in chronic neutropenic disorders and for general corporate purposes, including G&A, capital expenditures, and working capital. Certain officers have indicated interest in purchasing shares at the public offering price. X4’s common stock trades on Nasdaq as “XFOR”; the last reported sale price was $3.10 on October 22, 2025. Shares outstanding were 7,959,947 as of June 30, 2025.